Table 1 Baseline characteristics and follow-up information of the gout and control groups

Baseline characteristics

 Age

63.5 ± 9.7

63.5 ± 9.7

0.979

 Male

72,642 (63.3%)

18,254 (63.4%)

0.724

 Hypertension

38,947 (33.9%)

15,613 (54.3%)

<0.001

 Hyperlipidemia

11,177 (9.7%)

6,566 (22.8%)

<0.001

 Diabetes mellitus

18,968 (16.5%)

6,504 (22.6%)

<0.001

 Coronary artery disease

16,937 (14.8%)

6,146 (21.4%)

<0.001

 Heart failure

3,604 (3.1%)

1,533 (5.3%)

<0.001

 Arrhythmia

11,678 (10.2%)

3,800 (13.2%)

<0.001

 Chronic obstructive pulmonary disease

21,789 (19.0%)

6,590 (22.9%)

<0.001

 Asthma

7,892 (6.9%)

2,698 (9.4%)

<0.001

 Stroke

5,771 (5.0%)

1,611 (5.6%)

<0.001

 Malignancy

5,484 (4.8%)

1,337 (4.6%)

0.341

 Chronic kidney disease

5,128 (4.5%)

2,479 (8.6%)

<0.001

 Parkinson's disease

1,296 (1.1%)

290 (1.0%)

0.077

Follow-up information

All dementia types

 Follow-up duration

4.3 ± 2.1

4.4 ± 2.0

<0.001

 New cases (incidence density)

5,905 (11.9)

1,214 (9.5)

 Vascular dementia

 Follow-up duration

4.4 ± 2.0

4.5 ± 2.0

<0.001

 New cases (incidence density)

991 (2.0)

210 (1.6)

Non-vascular dementia

 Follow-up duration

4.3 ± 2.0

4.5 ± 2.0

<0.001

 New cases (incidence density)

4,914 (9.9)

1,004 (7.8)

Alzheimer's disease

 Follow-up duration

4.4 ± 2.0

4.5 ± 2.0

<0.001

 New cases (incidence density)

542 (1.1)

102 (0.8)